Founder and Chief Executive Officer

Ansar has held senior Director roles spanning Global Commercial and R&D at AstraZeneca over 12 years.

He supported the development, approval and commercialisation of 8 drugs including cancer medicines Iressa and Lynparza.

Ansar received a BSc in Genetics from King's College London and undertook his PhD training in Statistical Genetics at the Institute of Psychiatry at King's College London and the University of Oxford.

Ansar portraits 300ppi-5.jpg


Chief Medical Officer

Ulf has over 30 years experience in leading oncology roles at Celgene, Takeda, Pfizer and Eli Lily. 

He served as Vice President of Oncology and Head of Solid Tumour Development at Celgene. He drove development and approval of Gemzar, Evista, Alimta, Revlimid and Abraxane.

Ulf received his Medical Degree and BSc in Medicine/Oncology from the Karolinska University where he held senior clinical oncology roles.


Theresa Bruce

Clinical Operations

Theresa has over 20 years of oncology clinical development experience, including VP Oncology Global Development at Chiltern, and Chief Operating Officer at Nexus Oncology.

Theresa has supported the development of a number of medicines including Zytiga, Kyprolis, Jakafi and Pacritinib.

Theresa received her MBA from PhD from the Glasgow Caledonian University.

Clare Wareing photo-2-cw-08-Jul-2014.jpg


Senior Regulatory Advisor

Bob has over 30 years experience in drug development at AstraZeneca, Pfizer, Wellcome & Zambon.

Bob served as Vice President of Global Regulatory Affairs at AstraZeneca with responsibility for oncology, infection, and personalised healthcare. 

Bob supported the development and approval of 16 drugs including cancer medicines Lynparza, Iressa and Caprelsa.

Bob received his degree in Pharmacy from the University of Bath, MSc in BioPharmacy from the University of London and an MBA from the Open University.